© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
November 30, 2021
Factors that affect the use of maintenance therapy, including anti-CD20 maintenance therapy, for newly diagnosed follicular lymphoma, and recommendations for assessing response to therapy.
The rationale for treating newly diagnosed follicular lymphoma with the anti-CD20 monoclonal antibody, obinutuzumab, in the first-line setting.
Goals of therapy and variables that affect how patients with newly diagnosed follicular lymphoma are managed with chemoimmunotherapy in the frontline setting, including during COVID-19.
Recommendations for assessing and risk stratifying patients with newly diagnosed follicular lymphoma, with special considerations regarding the current role of molecular testing.
Similarities between the management of a hypothetical case of newly diagnosed follicular lymphoma compared with what is done in real-world practice.
In an interview with Targeted Oncology, Ruben Niesvizky, MD, discussed current efficacy outcomes in multiple myeloma and how the introduction of the car-BIRD regimen may improve upon them.
November 29, 2021
Marshall Posner, MD, discusses a study exploring the use of HB-201 and HB-202 vaccines in patients with HPV16-positive cancers.
During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the recommended approach to front-line treatment of castration-resistant prostate cancer.
Erika Hamilton, MD, discusses the mechanism of action of rebastinib, which is currently being explored in combination with weekly paclitaxel 1b/2 study of patients with platinum-resistant ovarian cancer.
Markus Joerger, MD, discussed the outcomes and prognostic factors of patients with cancer won contract COVID-19 in an interview with Targeted Oncology.
Efficacy signals have been shown in 100% of patients with metastatic prostate cancer treated with a new formulation of cabazitaxel.
After 40 years, a novel agent may be on the fast track to becoming the first drug to improve the standard of care for patients with metastatic colorectal cancer.